We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sensitivity of Enhanced Immunoassays Evaluated for Dengue

By LabMedica International staff writers
Posted on 13 Jul 2011
A newly developed blood test for Dengue Fever, that combines an assay for the virus' nonstructural protein 1 (NS1) with a commercial immunoassay test, has been evaluated. More...


The use of dengue NS1 antigen detection in combination with antiglycoprotein E immunoglobulins IgM and IgG serology can significantly increase the sensitivity of acute dengue diagnosis and enhances the clinical utility of rapid immunochromatographic testing for dengue.

In a retrospective study, led by scientists at the Research and Development Unit at Alere (Brisbane, Australia), the Dengue Early Rapid test was tested using stored acute plasma samples from 100 clinically suspected dengue patients, but with no laboratory evidence of acute or recent dengue virus infection and 198 samples from patients with laboratory-confirmed dengue. The performance of the Dengue Early Rapid test in combination with the IgM/IgG Rapid test was evaluated in Malaysia with 263 laboratory-confirmed positive and 30 negative samples.

In Vietnam the sensitivity and specificity of the test was 69.2% and 96% respectively, while in Malaysia the performance was similar with 68.9% sensitivity and 96.7% specificity compared to a real-time polymerase chain reaction test (RT-PCR). Importantly, when the PanBio Dengue Early Rapid test (PanBio Diagnostics; Sinnamon Park, QLD, Australia) was used in combination with their Dengue Duo cassette IgM/IgG test, sensitivity increased to 93.0%. When the two tests were compared at each day post-onset of illness, there was clear differentiation between the antigen and antibody markers.

The authors concluded that that a combined testing approach for both circulating NS1 antigen and antibody responses to the glycoprotein E of the virus can significantly improve diagnostic sensitivity compared to the detection of NS1 alone. Importantly, the combined antigen and antibody testing approach also provides an expanded window of detection from as early as the first day after the onset of illness. The study was published online in June 2011, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Alere
PanBio Diagnostics




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.